Krystal Biotech (KRYS) Competitors

Genmab A/S (NASDAQ:GMAB) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Does the media prefer GMAB or KRYS?

In the previous week, Krystal Biotech had 11 more articles in the media than Genmab A/S. MarketBeat recorded 20 mentions for Krystal Biotech and 9 mentions for Genmab A/S. Krystal Biotech's average media sentiment score of 0.88 beat Genmab A/S's score of 0.67 indicating that Krystal Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	10 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in GMAB or KRYS?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 13.7% of Krystal Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is GMAB or KRYS more profitable?

Krystal Biotech has a net margin of 40.85% compared to Genmab A/S's net margin of 37.53%. Genmab A/S's return on equity of 21.03% beat Krystal Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Krystal Biotech	40.85%	15.21%	13.81%

Which has higher valuation and earnings, GMAB or KRYS?

Genmab A/S has higher revenue and earnings than Krystal Biotech. Genmab A/S is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	5.06	$1.14B	$1.99	12.39
Krystal Biotech	$290.52M	14.99	$89.16M	$4.92	30.59

Do analysts rate GMAB or KRYS?

Genmab A/S presently has a consensus price target of $37.60, suggesting a potential upside of 52.54%. Krystal Biotech has a consensus price target of $210.38, suggesting a potential upside of 39.79%. Given Genmab A/S's higher probable upside, equities analysts clearly believe Genmab A/S is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Krystal Biotech	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk and volatility, GMAB or KRYS?

Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Summary

Krystal Biotech beats Genmab A/S on 10 of the 16 factors compared between the two stocks.